Complete response induced by half dose of sorafenib administration in advanced hepatocellular carcinoma with peritoneal dissemination

• Published in: Kanzo Vol. 55; no. 2; pp. 100 - 105
• Main Authors: Morimoto, Naoki, Isoda, Norio, Ootake, Toshiya, Watanabe, Shunji, Tsukui, Mamiko, Miyata, Natsumi, Hirosawa, Takuya, Nagamine, Nobuhiko, Sugano, Kentaro
• Format: Journal Article
• Language: Japanese
• Published: The Japan Society of Hepatology 20.02.2014
• Subjects: complete response; hepatocellular carcinoma; peritoneal dissemination; RECIST; sorafenib
• ISSN: 0451-4203; 1881-3593
• DOI: 10.2957/kanzo.55.100

A 87-year-old man with chronic hepatitis C and hepatocellular carcinoma (HCC) treated by repeated transcatheter arterial chemoembolization (TACE) and/or percutaneous ethanol injection therapy in the other hospital was referred to our institution. One year after, recurrent HCC was pointed out in the segment 8 near the past treated lesion, we performed TACE twice. Six months later, rapidly elevated alpha-fetoprotein level as well as multiple nodules adjacent the liver were detected which were diagnosed as peritoneal dissemination of HCC. Considering his age, half dose of sorafenib (400 mg per day) was administered. Following sorafenib administration the lesions markedly shrank and complete response (CR) according to Response Evaluation Criteria In Solid Tumors (RECIST) was achieved within five months. Treatment with even reduced dosage (200 mg per day) has been continued over one year, there is no clinical evidence of recurrence. To our knowledge, this is the first case achieved CR in advanced HCC with peritoneal dissemination successfully treated with a half dose of sorafenib.